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Introduction
Autonomous thyroid adenomas (ATAs) are a major cause of 
hyperthyroidism, especially in iodine-deficient areas (1, 2). The 
thyroid-stimulating hormone (TSH) plays a major role in con-
trolling the function and growth of thyroid cells. Binding of TSH 
to its receptor stimulates cAMP production and the subsequent 
activation of protein kinase A (PKA), leading to thyroid hormone 
production and cell proliferation. Consistently, activating muta-
tions in the TSH receptor (TSHR) have been found in up to 70% 
of ATAs (1, 3, 4). In addition, a minority of these tumors carry an 
activating mutation in the Gs protein α subunit (GNAS) gene (1, 
3, 4). While it is well established that constitutive activation of 
the cAMP/PKA pathway plays an important role in uncontrolled 
thyroid hormone secretion, it is presently unclear whether this is 
sufficient to induce the formation and/or expansion of thyroid 
adenomas. Moreover, the pathogenesis of a relevant fraction 
(approximately 30%) of ATAs that do not harbor TSHR or GNAS 
mutations is presently unknown. Only a minor fraction of the 
TSHR and GNAS mutation–negative tumors identified in early 
studies may represent false negatives (5, 6).
Whole-exome sequencing of matched tumor and normal 
samples is a powerful method for identifying somatic mutations 
implicated in tumor development. This approach is particularly 
effective in the case of well-differentiated tumors, which harbor 
few mutations. Using this approach, the molecular pathogenesis 
of several endocrine diseases associated with hormone hyperse-
cretion was recently clarified (7–9). Above all, this led to the iden-
tification of mutations in the catalytic α subunit of PKA (PRKACA) 
as being responsible for Cushing’s syndrome due to cortisol- 
secreting adrenocortical adenomas (8).
In this study, we performed next-generation whole-exome 
sequencing in a large series of ATAs to investigate the genetic 
alterations underlying these tumors. We found that a relevant 
fraction of ATAs carry a recurrent hot-spot mutation in a key gene 
involved in the regulation of cell differentiation and proliferation.
Results and Discussion
By performing whole-exome sequencing in 19 ATAs and paired 
normal samples, we identified a total of 94 candidate somatic 
mutations (81 missense, 5 nonsense, 3 frameshift, 3 direct splic-
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was not present in 6,951 in-house exomes nor in 60,706 exomes 
in the Exome Aggregation Consortium (ExAC) Browser (http://
exac.broadinstitute.org/; see Supplemental Methods for further 
details). This recurrent pattern of a heterozygous somatic muta-
tion was highly suggestive of a gain-of-function mode of action. 
No correlation was found between the mutational status and the 
available clinical data (Supplemental Table 3), including age at 
surgery, tumor size, and thyroid function tests (TSH, FT4, and 
FT3 levels as well as AbTg and AbTPO positivity).
On the basis of these initial results, we screened a large 
series of thyroid nodule samples (n = 304) for the presence of the 
hot-spot EZH1 c.1712A>G mutation. These samples comprised 
94 ATAs diagnosed in adults, 29 ATAs diagnosed in children 
and adolescents, 59 normal surrounding tissue samples (NSTs) 
of ATAs, 82 scintigraphically cold (i.e., nonfunctioning) thyroid 
nodules (CTNs), 16 follicular thyroid carcinomas (FTCs), and 24 
papillary thyroid carcinomas (PTCs). Interestingly, the hot-spot 
EZH1 mutation was found in 25 of 94 (27%) of the adult ATAs 
but not in any of the other samples (Figure 1B). A summary of 
the clinical parameters and mutational status of the adult ATA 
patients is presented in Supplemental Table 4. The absence of the 
hot-spot EZH1 mutation in FTCs and PTCs suggests that ATAs 
carrying this mutation are not a precursor to carcinoma. Further-
ing, and 2 indel; median: 4 somatic mutations in exonic regions 
per ATA sample; range: 0–12; Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI84894DS1). On the basis of a prediction of functional effects 
with the PolyPhen-2 software, 28 mutations were classified as 
probably damaging, 12 as possibly damaging, and 37 as benign. A 
detailed list of the observed somatic mutations is provided in Sup-
plemental Table 1. These mutations affected a total of 84 genes, 
78 of which were associated with a Gene Ontology (GO) term. A 
canonical pathway analysis (Supplemental Table 2) recognized 
the PDGF receptor pathway (n = 5 genes) and the GPCR pathway 
(n = 9 genes) as most significantly represented. The latter includ-
ed 5 GPCRs (TSHR, galanin receptor 2 [GALR2], olfactory recep-
tor family 2 subfamily G member 2 [OR2G2], olfactory receptor 
family 5 subfamily M member 3 [OR5M3], and taste 1 receptor 
member 2 [TAS1R2]; see also Appendix 1 and Supplemental 
Figure 2), the Gs protein α subunit (GNAS), adenylyl cyclase 9 
(ADCY9), and the ribosomal protein S6 kinase (RPS6KA3). Muta-
tions affecting 3 genes (enhancer of zeste homolog 1 [EZH1], thy-
roglobulin [TG], and TSHR) were found in at least 2 samples and 
were therefore considered to be recurrent. In particular, a hot-
spot substitution (c.1712A>G; p.Gln571Arg) in EZH1 was found in 
4 tumors (21% of cases) (Figure 1A). The c.1712A>G substitution 
Figure 1. Identification of a hot-spot somatic EZH1 mutation in ATAs. (A) Sequence chromatogram of an ATA sample carrying the heterozygous c.1712A>G 
mutation. A WT sample is shown for comparison. (B) Frequency of the EZH1 c.1712A>G mutation in different types of thyroid nodules. *P < 0.05,  
**P < 0.01, ***P < 0.001, and ****P < 0.0001 by χ2 test. (C and D) Grouping of the samples according to their mutational state in the exome-sequencing 
data (C) and validation cohort (D). mut, mutation.
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divided into 5 groups (Figure 1C). Similar results were obtained 
in the validation cohort when considering TSHR and EZH1 muta-
tions (Figure 1D). In the validation cohort, approximately one-
third (21 of 62, 34%) of the TSHR mutation–positive ATAs har-
bored an EZH1 c.1712A>G mutation. Similar allelic percentages 
in a subgroup of 8 ATAs suggested a possible clonal origin of the 
cells with both mutations (Supplemental Figure 3).
EZH1 codes for a catalytic subunit of the polycomb repres-
sive complex 2 (PRC2), which is implicated in the maintenance 
of embryonic stem cell pluripotency and plasticity. EZH1, a SET 
domain–containing histone methyltransferase, exerts its effects 
by catalyzing the mono-, di- and trimethylation of histone H3 at 
Lys27, leading to transcriptional repression of the associated genes 
(11, 12). PRC2 has been linked to the aggressiveness of various 
cancers (13, 14), and selective EZH1/2 inhibitors have been pro-
posed as a novel anticancer strategy (15).
more, the lack of EZH1 mutations in pediatric ATAs suggests that 
these adenomas might represent a separate entity or that EZH1 
mutations might be acquired later in the natural history of these 
tumors. No EZH1 mutations were found in either the thyroid tis-
sue or peripheral leukocytes of members of a family with the rare 
condition of nonautoimmune hyperfunctioning thyroid hyper-
plasia associated with germline, activating TSHR mutations 
(10), nor were these mutations found in a 2-year-old female with 
a sporadic case. Remarkably, in the ATA group investigated by 
exome sequencing, EZH1 mutations were found only in samples 
carrying known mutations in other genes of the cAMP pathway, 
i.e., TSHR (n = 2) and GNAS (n = 1), or a potentially damaging 
mutation in ADCY9 (n = 1). Considering the known mutations 
affecting GPCR signaling (TSHR, GNAS), the hot-spot EZH1 
mutation, and variations in other genes of the GPCR-signaling 
pathway, the ATAs analyzed by exome sequencing could be 
Figure 2. Location of the Gln571Arg mutation in EZH1. (A) Sequence alignment of the region corresponding to Gln571 in EZH1 from different species. 
The sequence of the closely related human EZH2 is included. (B) Predicted overall structure of PRC2 (based on ref. 18). (C) Position of the residue 
corresponding to Gln571. Since no structural data are available for EZH1, a structure of the catalytic domain of EZH2 (Protein Data Bank [PDB] ID: 4MI5; 
95% homology) is shown. The positions of the substrate and cofactor S-adenosyl-L-homocysteine (SAH) are based on an alignment with human H3K9 
methyltransferase (PDB ID: 3HNA).
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H3 methylation in a subset of ATA samples with or without the 
EZH1 mutation. All analyzed ATAs with EZH1 mutation had high-
er trimethylation levels and a tendency toward lower dimethyla-
tion levels  compared with those detected in both the correspond-
ing NST samples and the EZH1 mutation–negative ATAs (Figure 
3C). The increase in histone H3 trimethylation is similar to that 
found with EZH2 mutations in follicular and diffuse large B cell 
lymphomas (16). However, the mechanism is probably different. 
The EZH2 mutations in B cell lymphomas affect residues (Y641 
and Y677) that are directly involved in substrate binding (14), 
thus altering the substrate specificity in favor of dimethylated his-
tone H3 and ultimately leading to increased Lys27 trimethylation 
(17). The EZH1 mutation found in our study (Gln571Arg) affects 
a solvent-exposed residue in a region that is highly conserved 
between EZH1 and EZH2. Given the information available for 
EZH2, this residue is probably not involved in substrate binding 
but might play a role in the interaction with the suppressor of 
zeste 12 homolog (SUZ12) subunit of PRC2 and the cofactor adi-
pocyte enhancer–binding protein 2 (AEBP2), which is required for 
optimal enzymatic activity (18, 19) (Figure 2, B and C). Thus, we 
investigated the interaction between the Gln571Arg mutant and 
PRC2 components (SUZ12, AEBP2, and embryonic ectoderm 
The amino acid change (Gln571Arg) identified in ATAs in 
this study involves a highly conserved amino acid in the catalytic 
(SET) domain of EZH1 (Figure 2A). The position of this residue in 
a PRC2 model based on the partially solved x-ray structure of the 
closely related homolog EZH2 (14) is shown in Figure 2, B and C. 
This amino acid immediately precedes a cysteine residue, which 
is directly involved in the coordination of a zinc atom in the sec-
ond zinc-binding domain (14).
Given these findings, we investigated whether the Gln571Arg 
mutation was affecting EZH1 activity in intact cells. For this pur-
pose, we transfected HEK293 cells with either WT or mutant 
EZH1 and evaluated histone H3 methylation using Abs specific 
to mono-, di-, or trimethylated Lys27. Expression levels of both 
WT and mutant EZH1 protein were similar, indicating that the 
Gln571Arg mutation was not affecting protein stability (Figure 
3A). Remarkably, expression of the Gln571Arg mutant caused 
a strong increase in histone H3 trimethylation, accompanied 
by a concomitant decrease in dimethylation (Figure 3A). More-
over, an increase in histone H3 methylation was observed upon 
expression of the Gln571Arg mutant in 2 rat thyroid cell models: 
transiently transfected PCCL3 and stably transfected Fischer rat 
thyroid (FRT) cells (Figure 3B). In addition, we analyzed histone 
Figure 3. Functional characterization of the Gln571Arg EZH1 
mutant. (A) Effect of EZH1 Gln571Arg on histone H3 meth-
ylation at Lys27. The methylation pattern in lysates from 
cells transfected with FLAG-tagged EZH1 WT/Gln571Arg 
or the empty expression vector (control) was evaluated by 
Western blot analysis with Abs against mono- (H3K27me1), 
di- (H3K27me2), and trimethylation (H3K27me3). The 
expression of transfected EZH1 was evaluated using an Ab 
against the FLAG tag. (B) H3K27 methylation in thyroid 
cell lines stably (FRT) or transiently (PCCL3) transfected 
with EZH1 WT/Gln571Arg. (C) H3K27 methylation in ATA 
samples with or without Gln571Arg EZH1 mutation and the 
corresponding NSTs. (D) Proliferation of FRT cells stably 
expressing EZH1 WT/Gln571Arg. Cell viability was measured 
with the MTT assay. Data (n = 8) are shown as the mean ± 
SEM. ***P < 0.001 versus control; §§P < 0.01 versus EZH1 WT; 
§§§P < 0.001 versus EZH1 WT. Statistical significance was 
determined by 2-way ANOVA, followed by Bonferroni’s post 
test (E) Western blot analysis of proliferative markers in FRT 
cells stably expressing EZH1 WT/Gln571Arg. Results in A, 
B, and E are representative of 3 independent experiments. 
p-H3, phosphorylated H3.
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Statistics. Statistical analyses were performed using GraphPad 
Prism 4.0 software (GraphPad Software). The Fisher’s exact or χ2 test 
was used to investigate dichotomic variables. Differences between 3 or 
more groups were assessed by 1-way or 2-way ANOVA. P values of less 
than 0.05 were considered statistically significant.
Study approval. Patients were recruited at the University of 
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approved by the ethics committee of each participating institution.
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development [EED]) by coimmunoprecipitation (Supplemental 
Figure 4). No differences were detected between WT and mutant 
EZH1 proteins, suggesting that the Gln571Arg mutation does not 
grossly alter these interactions. Detailed structural studies will 
be required to further dissect the mechanisms underlying the 
increased activity caused by the Gln571Arg mutation.
Finally, we evaluated whether the EZH1 Gln571Arg substitu-
tion was affecting the proliferation of thyroid cells. For this pur-
pose, we generated FRT cells stably expressing WT EZH1 or the 
Gln571Arg mutant. Stable expression of the Gln571Arg mutant 
was associated with increased cell proliferation (Figure 3D). This 
effect was accompanied by a strong increase in the levels of cyclin 
D1 and histone H3 phosphorylation at Ser10, two cell proliferation 
markers (Figure 3E). In addition, we compared the effects of tran-
sient EZH1 transfection in 2 FRT clones stably expressing the WT 
TSHR or an activating TSHR mutant (V597F) (20). In contrast to 
transfection of WT EZH1, which had only a moderate proliferative 
effect, transfection of the mutant EZH1 caused a strong increase of 
cell proliferation in both cell lines (Supplemental Figure 5). These 
data suggest that the Gln571Arg mutant has a relevant impact on 
the proliferation of thyroid cells and can increase cell proliferation 
also in the presence of an activating TSHR mutant.
In conclusion, this study identifies EZH1 mutations as the 
second most frequent genetic alteration in ATAs. Gain-of-func-
tion TSHR mutations may well be sufficient to support thyroid 
autonomy and hyperplasia, as thyroid-stimulating Abs (TSAbs) 
do in Graves’ disease. However, we propose that their associa-
tion with EZH1 mutations such as those found in a relevant sub-
set of ATAs in this study — or with other still-unknown events 
giving advantage over normal thyroid cells — might further pro-
mote adenoma growth according to a “2-hit” model. Testing for 
the EZH1 Gln571Arg hot-spot mutation might help in the molec-
ular diagnosis and classification of thyroid nodules. Moreover, 
interfering with EZH1 function might be of potential therapeu-
tic benefit in thyroid disorders associated with increased cell 
proliferation. Additional mutations and/or pathogenic mecha-
nisms remain to be identified for cases that are both TSHR and 
EZH1 mutation negative.
Methods
Further information can be found in the Supplemental Methods. 
See the complete unedited blots in the supplemental material.
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